|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
P276-00
Description of P276-00: P276-00
is a flavone and cyclin dependent kinase (CDK) inhibitor with
potential antineoplastic activity. P276-00 selectively binds to and
inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine
kinases that play key roles in the regulation of the cell cycle and
cellular proliferation. Inhibition of these kinases leads to cell cycle
arrest during the G1/S transition, thereby leading to an induction of
apoptosis, and inhibition of tumor cell proliferation. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
Piramal Life Sciences
|
MedKoo Code#: 202118
|
|
Name: P276-00
|
|
CAS#:
Synonym: P276,
P276-00
IUPAC/Chemical name:
2-Aromatic-Substituted-5,7-dihydroxy-8-(2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-chromen-4-one
|
|
Chemical structure: |
|
|
|
Theoretical analysis: |
|
|
|
Availability and price:
This agent
is not in stock, which may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
1: Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao
SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits
HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Prostate Cancer Prostatic Dis. 2011 Nov 15. doi: 10.1038/pcan.2011.51. [Epub
ahead of print] PubMed PMID: 22083267.
2: Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent
kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by
inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Leuk Res. 2011 Jun;35(6):821-30. Epub 2011 Jan 8. PubMed PMID: 21216463.
3: Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S,
Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa
Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S,
Parikh H, Chabner B, Scadden D, Anderson KC. Preclinical activity of
P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the
therapy of multiple myeloma. Leukemia. 2009 May;23(5):961-70. Epub 2009
Jan 8. PubMed PMID: 19151776.
4: Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S,
Sivakumar M, Maier A, Fiebig HH, Sharma S. P276-00, a novel cyclin-dependent
inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant
cells and significant in vivo efficacy in tumor models. Mol Cancer Ther.
2007 Mar;6(3):926-34. PubMed PMID: 17363487.
5: Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S,
Lal B, Sharma S. In vitro antitumor properties of a novel cyclin-dependent
kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25. PubMed
PMID: 17363486.
6: Radvansky GA, Zacks RT, Hasher L. Age and inhibition: the retrieval
of situation models. J Gerontol B Psychol Sci Soc Sci. 2005
Sep;60(5):P276-8. PubMed PMID: 16131622; PubMed Central PMCID:
PMC1751467.
7: Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y,
Kawakami Y. Binding of beta 2-glycoprotein I to anionic phospholipids
facilitates processing and presentation of a cryptic epitope that
activates pathogenic autoreactive T cells. Blood. 2005 Feb
15;105(4):1552-7. Epub 2004 Oct 14. PubMed PMID: 15486070.
8: Mäntylä T. Remembering to remember: adult age differences in
prospective memory. J Gerontol. 1994 Nov;49(6):P276-82. PubMed PMID:
7963283.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
